SCHEMBL5526754

SCHEMBL5526754

CCN(CC)Cc1ccc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CCN(c5ccccc5C#N)CC4)c(OC(F)(F)Cl)c32)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 6/20 0.40
LMNA P02545 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 7/20 0.38
ALDH1A1 P00352 3/20 0.38
POLB P06746 1/20 0.38
HSP90AA1 P07900 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
HPGD P15428 3/20 0.38
HSD17B10 Q99714 3/20 0.38
TOP2A P11388 3/20 0.37
TOP2B Q02880 2/20 0.37
USP2 O75604 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5523951 0.91 TOP1 (0.47) TOP1LMNAMEN1KMT2AKDM4E
SCHEMBL5525220 0.91 PIK3CG (0.37) TOP1LMNAMEN1KMT2AKDM4E
SCHEMBL5530221 0.88 LMNA (0.45) TOP1LMNAMEN1KMT2AKDM4E
SCHEMBL14417364 0.87 MLLT1 (0.40) TOP1LMNAMEN1KMT2AKDM4E
SCHEMBL5530834 0.87 KDM4E (0.43) TOP1LMNAMEN1KMT2AKDM4E
SCHEMBL5523908 0.87 PIM1 (0.43) TOP1LMNAMEN1KMT2AKDM4E
SCHEMBL5522861 0.86 TOP1 (0.39) TOP1LMNAMEN1KMT2AKDM4E
SCHEMBL5525061 0.85 TOP1 (0.36) TOP1LMNAMEN1KMT2AKDM4E
SCHEMBL5531014 0.85 HPGD (0.44) TOP1LMNAMEN1KMT2AKDM4E
SCHEMBL5524270 0.84 TOP1 (0.48) TOP1LMNAMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213339-A1 Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-13 US claimed
US-20070213339-A1 Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-13 US disclosed
US-20070213339-A1 Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-13 US disclosed
US-20070213339-A1 Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-13 US disclosed
EP-1732897-A1 QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS Bayer Pharmaceuticals Corporation (US) 2006-12-20 EP disclosed
WO-2005097752-A1 QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS BAYER PHARMACEUTICALS CORPORATION (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213339-A1 Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions TP53, RB1, HRAS TOP1 39/4885LMNA 1366/4885MEN1 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.